UPDATE 1-Wyeth, Progenics drug misses goal in Phase 3 study
NEW YORK May 22 (Reuters) - Wyeth WYE.N and Progenics Pharmaceuticals Inc (PGNX.O) said on Thursday that an intravenous form of their Relistor drug failed to meet its main goal in a late-stage study for addressing gastrointestinal issues following surgery.
The Phase 3 study, which also failed to meet secondary goals, confirms earlier findings of the drug used for the condition, known as post-operative ileus. Progenics and Wyeth said they would study the results to determine whether to continue development of the intravenous form and this use.
The companies also said a mid-stage study of an oral form of Relistor for the treatment of opioid-induced constipation showed positive activity. The Phase 2 trial involved 122 patients with chronic, non-malignant pain such as back pain or osteoarthritis. Another Phase 2 trial of the oral formulation is ongoing.
Last month, an injection form of Relistor won U.S. approval for relieving constipation that often occurs with the use of morphine or other opioid painkillers. The drug is the first approved product for Progenics. (Reporting by Lewis Krauskopf, editing by Maureen Bavdek and Lisa Von Ahn)